Private Company Edition: In the first week of April, Cure Ventures launched with a $350m fund, the Alzheimer’s Drug Discovery Fund received $200m for its venture philanthropy strategy and Canaan revealed $850m in new funds. Also, OnKure raised $53.7m and Phlow closed a $36m series B round. 

Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.

Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.